Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Sep 3;7(1):e000703.
doi: 10.1136/bmjdrc-2019-000703. eCollection 2019.

Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery

Saumeth Cardona #  1 , Katerina Tsegka #  1 , Francisco J Pasquel  1 , Maya Fayfman  1 , Limin Peng  2 , Sol Jacobs  1 , Priyathama Vellanki  1 , Michael Halkos  3 , Robert A Guyton  3 , Vinod H Thourani  3 , Rodolfo J Galindo  1 , Guillermo Umpierrez  1
Affiliations
Randomized Controlled Trial

Sitagliptin for the prevention of stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery

Saumeth Cardona et al. BMJ Open Diabetes Res Care. .

Abstract

Aims: To determine if treatment with sitagliptin, a dipeptidyl peptidase-4 inhibitor, can prevent stress hyperglycemia in patients without diabetes undergoing coronary artery bypass graft (CABG) surgery.

Methods: We conducted a pilot, double-blinded, placebo-controlled randomized trial in adults (18-80 years) without history of diabetes. Participants received sitagliptin or placebo once daily, starting the day prior to surgery and continued for up to 10 days. Primary outcome was differences in the frequency of stress hyperglycemia (blood glucose (BG) >180 mg/dL) after surgery among groups.

Results: We randomized 32 participants to receive sitagliptin and 28 to placebo (mean age 64±10 years and HbA1c: 5.6%±0.5%). Treatment with sitagliptin resulted in lower BG levels prior to surgery (101±mg/dL vs 107±13 mg/dL, p=0.01); however, there were no differences in the mean BG concentration, proportion of patients who developed stress hyperglycemia (21% vs 22%, p>0.99), length of hospital stay, rate of perioperative complications and need for insulin therapy in the intensive care unit or during the hospital stay.

Conclusion: The use of sitagliptin during the perioperative period did not prevent the development of stress hyperglycemia or need for insulin therapy in patients without diabetes undergoing CABG surgery.

Keywords: CABG; DPP-4 inhibitors; stress hyperglycemia.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Schmeltz LR, DeSantis AJ, Thiyagarajan V, et al. . Reduction of surgical mortality and morbidity in diabetic patients undergoing cardiac surgery with a combined intravenous and subcutaneous insulin glucose management strategy. Diabetes Care 2007;30:823–8. 10.2337/dc06-2184 - DOI - PubMed
    1. McAlister FA, Man J, Bistritz L, et al. . Diabetes and coronary artery bypass surgery: an examination of perioperative glycemic control and outcomes. Diabetes Care 2003;26:1518–24. 10.2337/diacare.26.5.1518 - DOI - PubMed
    1. Carvalho G, Moore A, Qizilbash B, et al. . Maintenance of normoglycemia during cardiac surgery. Anesth Analg 2004;99:319–24. 10.1213/01.ANE.0000121769.62638.EB - DOI - PubMed
    1. Weintraub WS, Stein B, Kosinski A, et al. . Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol 1998;31:10–19. 10.1016/S0735-1097(97)00441-5 - DOI - PubMed
    1. Furnary AP, Zerr KJ, Grunkemeier GL, et al. . Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999;67:352–60. 10.1016/S0003-4975(99)00014-4 - DOI - PubMed

Publication types

MeSH terms